Dyne Therapeutics Inc. Common Stock vs Tencent Music Entertainment Group - ADR — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Tencent Music Entertainment Group - ADR trades at $8.32 (market cap $13.81B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 4.8× Dyne Therapeutics Inc. Common Stock's market cap, and Tencent Music Entertainment Group - ADR pays a 2.82% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Tencent Music Entertainment Group - ADR for 68 Days on average.
| DYN | TME | |
|---|---|---|
Market Cap | $2.86B | $13.81B |
Volume | 3,341,579 | 6,097,902 |
Sector | Health | Media |
52-Week High | $26.78 | $23.71 |
52-Week Low | $14.60 | $7.74 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $2.18B | $11.76B |
Dividend Yield | — | 2.82% |
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Tencent Music Entertainment (TME) trades at $8.48, up 0.36% on the day, with a bullish technical signal and strong fundamentals. Revenue grew to $32.9B in 2025, with net income surging to $11.06B, and valuation ratios like a P/E of 9.94 appear attractive. Recent news highlights a $1B notes offering and a $400M share repurchase program, signaling financial discipline.
The outlook is positive with a consensus price target of $12.50, offering 47% upside, but risks include intense competition and regulatory oversight. Earnings have been mixed, with Q2 2026 beating expectations but Q1 and Q4 2025 missing, indicating potential volatility in performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →